<DOC>
	<DOC>NCT01219543</DOC>
	<brief_summary>This is Phase I, open-label and dose escalation study to evaluate the safety and tolerability of AZD1480(JAK2 inhibitor) in Asian patients with advanced solid tumors (Part A and C) and in patients with advanced HCC (Part B) in the escalation phase, EGFR or ROS mutant NSCLC and non-smokers with lung metastasis and gastric cancer in the expansion phase and to evaluate daily and BID dosing.</brief_summary>
	<brief_title>A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Male or female aged 18 years or older For Part A and C: Histological or cytological confirmation of a solid malignant tumour refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma &amp; HCC are excluded. For Expansion : Histological or cytological confirmation of Expansion 1: EGFR and/or ROS mutant NSCLC or Nonsmokers with lung metastasis Expansion 2: Gastric cancer or solid tumour with biopsy available (consenting paired biopsies)refractory to standard therapies or for which no standard therapies exist. Patients with lymphoma &amp; HCC are excluded. For Part B : Advanced or metastatic HCC, unresectable and incurable with ablative therapy or TACE, with no standard therapy available. Eastern Cooperative Oncology Group (ECOG) performance status 01 with no deterioration over the previous 2 weeks For Part B : ChildPugh liver function status classified as A to B7 For any other chemotherapy, immunotherapy or anticancer agents, within 5 half lives or 3 weeks must have elapsed from treatment to of the first dose of investigational product, whichever is shorter. With the exception of alopecia, any unresolved toxicities from prior therapy â‰¥ Grade 2 of CTCAE V4.02 at the time of starting study (except LFTs for HCC patients, which may be Grade 2 at the time of starting the study) Any of the following conditions:Interferon treatment for HBV and HCV Prior Liver Transplantation Inadequate bone marrow reserve or organ function as demonstrated by laboratory values Evidence of established interstitial lung disease(ILD) on baseline high resolution computerized tomography(HRCT)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Advanced solid malignancies</keyword>
	<keyword>Child-Pugh A to B7 advanced hepatocellular carcinoma</keyword>
	<keyword>EGFR and/or ROS mutant NSCLC</keyword>
	<keyword>Non-smokers with lung metastasis</keyword>
	<keyword>Gastric cancer</keyword>
	<keyword>Solid tumour</keyword>
	<keyword>AZD1480</keyword>
	<keyword>JAK1/JAK2 kinase inhibitor</keyword>
</DOC>